X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Beyond output and employment: The impact of America’s biopharmaceutical industry

By Ryan Garofalo  |    February 11, 2021
Particularly in recent times, biopharmaceutical companies have become increasingly important to the American economy. But just how valuable are they? In the United States, these businesses support...   Read More

Preserving U.S. innovation worldwide is more important than ever

By Megan Van Etten  |    January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...   Read More

American biopharmaceutical manufacturing: Fueling economic growth now and for years to come

By Nicole Longo  |    December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...   Read More

Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions

By Megan Van Etten  |    October 2, 2020
The first Friday of October marks Manufacturing Day, an annual recognition of the critical role manufacturing industries play in powering innovation and generating jobs and economic growth for...   Read More

America’s global leadership in biopharmaceutical manufacturing

By Nicole Longo  |    June 4, 2020
Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America’s leadership and suggesting our reliance on other...   Read More

New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output

By Sarah Sutton  |    February 12, 2020
Across the country, the biopharmaceutical sector supports millions of jobs in its pursuit to discover ground-breaking treatments and cures for patients around the world.   Read More

What you need to know about H.R. 3

By Tom Wilbur  |    December 12, 2019
Speaker of the House Nancy Pelosi’s drug pricing proposal, H.R. 3, which is being voted on in the U.S. House of Representatives today, is unprecedented in size and scope. It dramatically expands...   Read More

New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines

By Nicole Longo  |    December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation

By Tom Wilbur  |    October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates